KR20040078122A - 2-아실아미노티아졸 유도체 또는 그 염 - Google Patents
2-아실아미노티아졸 유도체 또는 그 염 Download PDFInfo
- Publication number
- KR20040078122A KR20040078122A KR10-2004-7010846A KR20047010846A KR20040078122A KR 20040078122 A KR20040078122 A KR 20040078122A KR 20047010846 A KR20047010846 A KR 20047010846A KR 20040078122 A KR20040078122 A KR 20040078122A
- Authority
- KR
- South Korea
- Prior art keywords
- substituted
- thiazol
- chlorothiophen
- cyclohexylpiperazin
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Abstract
Description
피험화합물 | pot. [nM] | 효율(%) |
실시예 9 | 10 | 87 |
실시예 16 | 2.4 | 93 |
실시예 66 | 14 | 99 |
실시예 103 | 18 | 97 |
실시예 214 | 15 | 106 |
실시예 250 | 6.7 | 87 |
실시예 272 | 3.3 | 96 |
실시예 276 | 8.7 | 100 |
실시예 280 | 4.9 | 107 |
실시예 328 | 9.0 | 88 |
비교화합물 1 | 4.4 | 101 |
비교화합물 2 | 2.1 | 96 |
비교화합물 3 | 6.9 | 96 |
rhTPO | 0.012 | 100 |
피험화합물 | 투여량[mg/kg p.o.] | 세포증식활성[%] |
실시예 16 | 10 | >80% |
실시예 66 | 10 | 61% |
실시예 214 | 10 | >80% |
실시예 250 | 10 | >80% |
실시예 272 | 10 | >80% |
실시예 276 | 10 | >80% |
실시예 280 | 10 | >80% |
실시예 328 | 10 | >80% |
비교화합물 1 | 100 | <10% |
비교화합물 2 | 100 | <10% |
비교화합물 3 | 100 | <10% |
Claims (17)
- 식(I)로 나타내어지는 2-아실아미노티아졸 유도체 또는 그 제약학적으로 허용되는 염을 유효성분으로 하는 혈소판 증가제:[식 중의 기호는 이하의 의미를 나타낸다.Ar1: 각각 치환되어 있을 수도 있는 아릴, 단환 방향족 헤테로환, 또는 2환계 축합 헤테로환(단, R1이 저급 알킬, -CO-저급 알킬, -COO-저급 알킬, -OH, -O-저급 알킬, -OCO-저급 알킬 및 할로겐으로 이루어지는 군으로부터 선택되는 하나 이상의 기로 각각 치환되어 있을 수도 있는 아릴 또는 피리딜이며, 또한, R2가 하기 식(II)로 나타내는 기일 때; 저급 알킬, -CO-저급 알킬, -COO-저급 알킬, -OH, -O-저급 알킬, -OCO-저급 알킬 및 할로겐으로 이루어지는 군으로부터 선택되는 하나 이상의 기로 각각 치환되어 있을 수도 있는 페닐 또는 피리딜을 제외한다.).R1: 각각 치환되어 있을 수도 있는 아릴 또는 단환 방향족 헤테로환.R2: 식(II), 식(III) 또는 식(IV)로 나타내는 기.[식 중의 기호는 이하의 의미를 나타낸다.n: 1∼3의 정수.m: 1∼3의 정수.여기에서, n 또는 m이 2 이상의 정수인 경우, CR20R21및 CR22R23은 각각 다른 기를 나타내더라도 된다.X: O, S, N-R26, C(-R27)-R28로 나타내는 기.E, G, J, L: 각각 독립적으로 N 또는 C-R29로 나타내는 기(단, 이들 중에서 최소한 하나는 C-R29를 나타낸다.).R20, R21, R22, R23, R26, R27, R28, R29: 동일 또는 다르고, -H; -OH; -O-저급 알킬; 치환되어 있을 수도 있는 저급 알킬; 치환되어 있을 수도 있는 사이클로알킬; 치환되어 있을 수도 있는 아릴; 치환되어 있을 수도 있는 아릴알킬; 치환되어 있을 수도 있는 방향족 헤테로환; 치환되어 있을 수도 있는 방향족 헤테로환 알킬; 치환되어 있을 수도 있는 비방향족 헤테로환; 치환되어 있을 수도 있는 저급 알케닐;치환되어 있을 수도 있는 저급 알킬리덴; -COOH; -COO-저급 알킬; -COO-저급 알케닐; -COO-저급 알킬렌-아릴; -COO-저급 알킬렌-방향족 헤테로환; 할로겐, -OH, -O-저급 알킬 또는 -O-아릴로 각각 치환되어 있을 수도 있는 저급 알킬 및 사이클로알킬로 이루어지는 군으로부터 선택되는 하나 이상의 기로 각각 치환되어 있을 수도 있는 카르바모일 또는 아미노; -NHCO-저급 알킬; 또는 옥소.R24, R25: 동일 또는 다르고, -H, 치환되어 있을 수도 있는 저급 알킬, 치환되어 있을 수도 있는 사이클로알킬, 또는 치환되어 있을 수도 있는 비방향족 헤테로환.]]
- 제1항에 있어서,R1이 하나 내지 3개의 할로겐으로 치환된 페닐 또는 티에닐(할로겐이 2개 또는 3개 치환하는 경우, 동일한 할로겐이라도 각각 다른 할로겐이어도 된다)이며; R2가 제1항 기재의 식(II)로 나타내는 기이며, n이 2이며, m이 2이며, X가 N-R26또는 C(-R27)-R28으로 나타내는 기이며; Ar1이 각각 치환되어 있을 수도 있는 페닐 또는 피리딜인 의약 조성물.
- 제1항 또는 제2항에 있어서,혈소판 감소증 치료제인 의약 조성물.
- 제1항 또는 제2항에 있어서,c-Mpl 리간드인 의약 조성물.
- 식(V)로 나타내는 2-아실아미노티아졸 유도체 또는 그 제약학적으로 허용되는 염:[식 중의 기호는 이하의 의미를 나타낸다.Ar2: 제1항 기재의 Ar1로 나타내는 기. 단, 인돌-2-일을 제외한다.R3: 제1항 기재의 R1로 나타내는 기.R4: 제1항 기재의 R2로 나타내는 기. 단, 식(IV)로 나타내는 기를 제외한다.]
- 제5항에 있어서,Ar2가 각각 치환되어 있을 수도 있는 페닐 또는 단환 방향족 헤테로환인 화합물.
- 제6항에 있어서,R3이 각각 치환되어 있을 수도 있는 페닐 또는 티에닐이며, R4가 제1항 기재의 식(II)로 나타내는 기이며, Ar2가 각각 치환되어 있을 수도 있는 페닐 또는 피리딜인 화합물.
- 제7항에 있어서,n이 2이며, m이 2이며, X가 N-R26또는 C(-R27)-R28로 나타내는 기인 화합물.
- 제8항에 있어서,R3이 하나 내지 3개의 할로겐으로 치환된 페닐 또는 티에닐(할로겐이 2개 또는 3개 치환하는 경우, 동일한 할로겐이라도 각각 다른 할로겐이어도 된다)인 화합물.
- 제9항에 있어서,R4가 4-(피페리딘-1-일)피페리딘-1-일, 4-프로필피페리딘-1-일, 4-사이클로헥실피페라진-1-일, 또는 4-프로필피페라진-1-일인 화합물.
- 제10항에 있어서,Ar2가, 2위 및 6위가 무치환이며, 3위가 -H, -F, -Cl 또는 -Br로 치환되어 있고, 5위가 -F, -Cl 또는 -Br로 치환되어 있고, 4위가 치환되어 있는 페닐; 또는 2위 및 4위가 무치환이며, 5위가 -F, -Cl 또는 -Br로 치환되어 있고, 6위가 치환되어 있는 피리딘-3-일인 화합물.
- 제11항에 있어서,Ar2가, -O-RY, -NH-RY, 치환되어 있을 수도 있는 피페리딘-1-일 및 치환되어 있을 수도 있는 피페라진-1-일로 이루어지는 군으로부터 선택되는 기로 4위가 치환되어 있는 페닐; 또는 -O-RY, -NH-RY, 치환되어 있을 수도 있는 피페리딘-1-일 및 치환되어 있을 수도 있는 피페라진-1-일로 이루어지는 군으로부터 선택되는 기로 6위가 치환되어 있는 피리딘-3-일인 화합물. (여기에서, RY란, -OH, -O-저급 알킬, 하나 또는 2개의 저급 알킬로 치환되어 있을 수도 있는 아미노, -CO2H, -CO-저급 알킬, 하나 또는 2개의 저급 알킬로 치환되어 있을 수도 있는 카르바모일, 시아노, 아릴, 방향족 헤테로환, 비방향족 헤테로환 및 할로겐으로 이루어지는 군으로부터 선택되는 하나 이상의 기로 치환되어 있을 수도 있는 저급 알킬을 나타낸다.)
- 제5항 내지 제12항 중 어느 한 항에 있어서,N-[4-(4-클로로티오펜-2-일)-5-(4-사이클로헥실피페라진-1-일)티아졸-2-일]-3-플루오로-4-히드록시벤즈아미드,3-클로로-N-[4-(4-클로로티오펜-2-일)-5-(4-사이클로헥실피페라진-1-일)티아졸-2-일]-4-(2-하이드록시에톡시)벤즈아미드,N-[4-(4-클로로티오펜-2-일)-5-(4-프로필피페리디노)티아졸-2-일]-2-메톡시이소니코틴아미드,N-[4-(4-클로로티오펜-2-일)-5-(4-사이클로헥실피페라진-1-일)티아졸-2-일]이소퀴놀린-6-카르복스아미드,3-클로로-N-[4-(4-클로로티오펜-2-일)-5-(4-프로필피페라진-1-일)티아졸-2-일]-4-(2-하이드록시에톡시)벤즈아미드,5-클로로-N-[4-(4-클로로티오펜-2-일)-5-(4-사이클로헥실피페라진-1-일)티아졸-2-일]-6-(3-하이드록시프로폭시)니코틴아미드,5-클로로-N-[4-(4-클로로티오펜-2-일)-5-(4-사이클로헥실피페라진-1-일)티아졸-2-일]-6-[(3-히드록시프로필)아미노]니코틴아미드,1-(3-클로로-5-{[4-(4-클로로티오펜-2-일)-5-(4-사이클로헥실피페라진-1-일)티아졸-2-일]카르바모일}-2-피리딜)피페리딘-4-카르복시산,1-(3-클로로-5-{[4-(4-클로로티오펜-2-일)-5-(4-프로필피페라진-1-일)티아졸-2-일]카르바모일}-2-피리딜)피페리딘-4-카르복시산,N-[4-(4-클로로티오펜-2-일)-5-(4-사이클로헥실피페라진-1-일)티아졸-2-일]-4-(4-시아노피페리디노)-3,5-디플루오로벤즈아미드,1-(2-클로로-4-{[4-(4-클로로티오펜-2-일)-5-(4-사이클로헥실피페라진-1-일)티아졸-2-일]카르바모일}페닐)피페리딘-4-카르복시산,1-(2-클로로-4-{[4-(4-클로로티오펜-2-일)-5-(4-사이클로헥실피페라진-1-일)티아졸-2-일]카르바모일}-6-플루오로페닐)피페리딘-4-카르복시산,1-(2-클로로-4-{[4-(4-클로로티오펜-2-일)-5-(4-프로필피페라진-1-일)티아졸-2-일]카르바모일}페닐)피페리딘-4-카르복스아미드,5-클로로-N-[4-(4-클로로티오펜-2-일)-5-(4-사이클로헥실피페라진-1-일)티아졸-2-일]-6-(4-하이드록시메틸피페리디노)니코틴아미드,1-(3-클로로-5-{[5-(4-사이클로헥실피페라진-1-일)-4-(4-플루오로페닐)티아졸-2-일]카르바모일}-2-피리딜)피페리딘-4-카르복시산,1-(3-클로로-5-{[5-(4-사이클로헥실피페라진-1-일)-4-(3-트리플루오로메틸페닐)티아졸-2-일]카르바모일}-2-피리딜)피페리딘-4-카르복시산,5-클로로-N-[4-(4-클로로티오펜-2-일)-5-(4-사이클로헥실피페라진-1-일)티아졸-2-일]-6-{4-[(2-메톡시에틸)카르바모일]피페리디노}니코틴아미드,5-클로로-N-[4-(4-클로로티오펜-2-일)-5-(4-사이클로헥실피페라진-1-일)티아졸-2-일]-6-{4-[(3-메톡시프로필)카르바모일]피페리디노}니코틴아미드, 또는 ,5-클로로-N-[4-(4-클로로티오펜-2-일)-5-(4-사이클로헥실피페라진-1-일)티아졸-2-일]-6-[4-(모르폴리노카보닐)피페리디노]니코틴아미드,또는 그 제약학적으로 허용되는 염.
- 제5항 내지 제13항 중 어느 한 항에 기재된 화합물을 유효성분으로 하는 의약 조성물.
- 제14항에 있어서,혈소판 증가제인 의약 조성물.
- 제14항에 있어서,혈소판 감소증 치료제인 의약 조성물.
- 제14항에 있어서,c-Mpl 리간드인 의약 조성물.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPJP-P-2002-00010447 | 2002-01-18 | ||
JPJP-P-2002-00010413 | 2002-01-18 | ||
JP2002010447 | 2002-01-18 | ||
JP2002010413 | 2002-01-18 | ||
PCT/JP2003/000270 WO2003062233A1 (fr) | 2002-01-18 | 2003-01-15 | Derive de 2-acylaminothiazole et son sel |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040078122A true KR20040078122A (ko) | 2004-09-08 |
KR101010905B1 KR101010905B1 (ko) | 2011-01-25 |
Family
ID=27615666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047010846A KR101010905B1 (ko) | 2002-01-18 | 2003-01-15 | 2-아실아미노티아졸 유도체 또는 그 염 |
Country Status (17)
Country | Link |
---|---|
US (4) | US7638536B2 (ko) |
EP (2) | EP1466912B1 (ko) |
JP (2) | JP4120586B2 (ko) |
KR (1) | KR101010905B1 (ko) |
CN (1) | CN1319967C (ko) |
BE (1) | BE2019C547I2 (ko) |
CA (1) | CA2472711C (ko) |
CY (2) | CY1114169T1 (ko) |
DK (1) | DK1466912T3 (ko) |
ES (2) | ES2416304T3 (ko) |
FR (1) | FR19C1072I2 (ko) |
HU (1) | HUS1900052I1 (ko) |
LU (1) | LUC00137I2 (ko) |
NL (1) | NL301020I2 (ko) |
PT (1) | PT1466912E (ko) |
SI (1) | SI1466912T1 (ko) |
WO (1) | WO2003062233A1 (ko) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
PT1466912E (pt) * | 2002-01-18 | 2013-06-28 | Astellas Pharma Inc | Derivado de 2-aciloaminotiazol ou seu sal |
DE60326436D1 (en) * | 2002-03-13 | 2009-04-16 | Janssen Pharmaceutica Nv | Aminoderivate als histone-deacetylase-inhibitoren |
AU2003268687A1 (en) * | 2002-09-30 | 2004-04-19 | Yamanouchi Pharmaceutical Co., Ltd. | Novel salt of 2-acylaminothiazole derivative |
KR100907317B1 (ko) | 2003-07-17 | 2009-07-13 | 아스텔라스세이야쿠 가부시키가이샤 | 2-아실아미노티아졸 유도체 또는 그의 염 |
EP1655291B1 (en) * | 2003-08-12 | 2016-08-03 | Shionogi & Co., Ltd. | Compounds having thrombopoietin receptor agonism |
BRPI0418082B8 (pt) | 2003-12-26 | 2021-05-25 | Kyowa Hakko Kirin Co Ltd | derivados de tiazol úteis como antagonistas de receptor de adenosina a2a |
WO2005118551A2 (en) * | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
CN1997371A (zh) * | 2004-07-06 | 2007-07-11 | 泽农医药公司 | 烟酰胺衍生物及其作为治疗剂的用途 |
JP4958787B2 (ja) * | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリジン誘導体 |
MX2007004765A (es) * | 2004-10-25 | 2007-07-09 | Ligand Pharm Inc | Compuestos y metodos que modulan la actividad de la trombopoyetina. |
RU2395505C2 (ru) | 2004-12-08 | 2010-07-27 | Ниссан Кемикал Индастриз, ЛТД | 3-этилиденгидразино-замещенные гетероциклические соединения в качестве активаторов рецептора тромбопоэтина |
TWI399368B (zh) | 2004-12-14 | 2013-06-21 | Nissan Chemical Ind Ltd | Amide compounds and thrombopoietin receptor activators |
JP4665769B2 (ja) * | 2005-01-12 | 2011-04-06 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体の製造法 |
JP4774995B2 (ja) * | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
JPWO2006137527A1 (ja) | 2005-06-23 | 2009-01-22 | 協和発酵キリン株式会社 | チアゾール誘導体 |
WO2007004038A1 (en) * | 2005-07-05 | 2007-01-11 | Pfizer Products Inc. | Aminothiazole derivatives as agonists of the thrombopoietin receptor |
WO2007036769A1 (en) * | 2005-07-05 | 2007-04-05 | Pfizer Products Inc. | Aminothiazole derivatives as agonists of the thrombopoietin receptor |
CA2614726A1 (en) * | 2005-07-13 | 2007-01-18 | Astrazeneca Ab | New pyridine analogues |
TWI368617B (en) | 2005-07-15 | 2012-07-21 | Nissan Chemical Ind Ltd | Thiophene compounds and thrombopoietin receptor activators |
JP5104752B2 (ja) | 2005-07-20 | 2012-12-19 | 日産化学工業株式会社 | ピラゾール化合物及びトロンボポエチンレセプター活性化剤 |
WO2007052808A1 (ja) | 2005-11-07 | 2007-05-10 | Nissan Chemical Industries, Ltd. | ヒドラジド化合物及びトロンボポエチンレセプター活性化剤 |
US20070203153A1 (en) * | 2005-11-08 | 2007-08-30 | Astellas Pharma Inc. | Compositions and methods for treating thrombocytopenia |
JP5157900B2 (ja) | 2006-06-07 | 2013-03-06 | 日産化学工業株式会社 | 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
ES2452032T3 (es) * | 2006-08-08 | 2014-03-31 | Akarx, Inc. | Composiciones y métodos para aumentar los niveles de plaquetas de la sangre en humanos |
JP5164510B2 (ja) * | 2006-10-06 | 2013-03-21 | 日本曹達株式会社 | 含窒素複素環化合物および有害生物防除剤 |
US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
UY30915A1 (es) * | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
US20110129550A1 (en) * | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
AU2008283357B2 (en) | 2007-07-31 | 2011-08-11 | Shionogi & Co., Ltd. | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity and intermediate thereof |
ES2331220B1 (es) * | 2007-10-02 | 2010-09-23 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
WO2009048953A1 (en) * | 2007-10-09 | 2009-04-16 | The Trustees Of The University Of Pennsylvania | Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells |
EA201001358A1 (ru) * | 2008-02-25 | 2011-04-29 | Мерк Патент Гмбх | Активаторы глюкокиназы |
US8476249B2 (en) | 2009-05-07 | 2013-07-02 | Glaxosmithkline Llc | Method of treating thrombocytopenia |
US8680150B2 (en) * | 2009-05-28 | 2014-03-25 | Ligand Pharmaceuticals, Inc. | Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors |
EP2464352A1 (en) * | 2009-08-14 | 2012-06-20 | Eisai Inc. | Use of e5501 for stimulating platelet production |
GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
GB201111704D0 (en) * | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
JP2014144916A (ja) | 2011-08-03 | 2014-08-14 | Astellas Pharma Inc | 2−アシルアミノチアゾール化合物の結晶 |
JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
AP2014007637A0 (en) | 2011-11-15 | 2014-05-31 | Takeda Pharmaceutical | Dihydroxy aromatic heterocyclic compound |
WO2013146754A1 (ja) * | 2012-03-27 | 2013-10-03 | 塩野義製薬株式会社 | Trpv4阻害活性を有する芳香族複素5員環誘導体 |
GB201222711D0 (en) | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
TWI647227B (zh) | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | 2-醯胺噻唑衍生物或其鹽 |
EP2970125B1 (en) | 2013-03-14 | 2018-07-18 | Dart Neuroscience (Cayman) Ltd. | Substituted naphthyridine and quinoline compounds as mao inhibitors |
JP6522602B2 (ja) | 2013-07-02 | 2019-05-29 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Rock阻害剤としての三環式ピリド−カルボキサミド誘導体 |
TW201506024A (zh) | 2013-07-02 | 2015-02-16 | 必治妥美雅史谷比公司 | 作為有效rock抑制劑的三環甲醯胺衍生物 |
UA122208C2 (uk) | 2014-06-06 | 2020-10-12 | Астеллас Фарма Інк. | Похідне 2-ациламінотіазолу або його сіль |
EP3196200B1 (en) * | 2014-08-26 | 2019-05-08 | Astellas Pharma Inc. | 2-aminothiazole derivatives or salt thereof as muscarinic m3 ligands for the treatment of bladder diseases |
WO2016068270A1 (ja) | 2014-10-31 | 2016-05-06 | 日産化学工業株式会社 | リガンド結合繊維及び当該繊維を用いた細胞培養基材 |
US20190315771A1 (en) * | 2016-09-08 | 2019-10-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Novel 2-acylaminothiazole derivative and preparation method therefor and use thereof |
CN106749226B (zh) * | 2017-03-15 | 2019-12-20 | 广东赛拓医药科技有限公司 | 一种avatrombopag马来酸盐晶型C的制备方法 |
CN107383000A (zh) * | 2017-08-07 | 2017-11-24 | 瑞阳制药有限公司 | 血小板增多剂的制备方法 |
WO2020044364A1 (en) | 2018-08-27 | 2020-03-05 | Mylan Laboratories Limited | Polymorphic forms of avatrombopag maleate |
RU2709496C1 (ru) * | 2019-08-01 | 2019-12-18 | Марат Феликсович Фазылов | Способ получения аватромбопага |
CN110586047B (zh) * | 2019-10-08 | 2022-03-11 | 辽宁工业大学 | 一种用于吸附铅离子的改性双醛淀粉制备方法 |
CN111620863A (zh) * | 2020-06-23 | 2020-09-04 | 苏州明锐医药科技有限公司 | 阿曲波帕的制备方法 |
CN115057854A (zh) * | 2022-04-19 | 2022-09-16 | 河北常山生化药业股份有限公司 | 马来酸阿伐曲泊帕中间体的制备方法 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5330998A (en) | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
US5256675A (en) * | 1989-08-07 | 1993-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same |
TW205041B (ko) | 1989-08-07 | 1993-05-01 | Fujisawa Pharmaceutical Co | |
JPH078863B2 (ja) | 1989-09-21 | 1995-02-01 | 久光製薬株式会社 | 新規なジフェニルチアゾール誘導体 |
IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
JPH03199451A (ja) | 1989-12-26 | 1991-08-30 | Asahi Chem Ind Co Ltd | エアージェットルーム用筬 |
FR2677356B1 (fr) * | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
US5250732A (en) * | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
JP3173876B2 (ja) | 1992-06-26 | 2001-06-04 | 日本パイオニクス株式会社 | 有害ガスの検知システム |
WO1995006635A1 (fr) | 1993-09-02 | 1995-03-09 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de carbamate et medicament le contenant |
KR970701174A (ko) | 1994-02-10 | 1997-03-17 | 오노다 마사요시 | 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same) |
AU4889496A (en) * | 1995-03-09 | 1996-10-02 | Kyowa Hakko Kogyo Co. Ltd. | Pyrrolocarbazole derivatives |
DE69632728T2 (de) | 1995-04-28 | 2004-10-14 | Banyu Pharmaceutical Co., Ltd. | 1,4-disubstituierte piperidinderivate |
EA001220B1 (ru) * | 1995-06-07 | 2000-12-25 | Глаксо Груп Лимитед | Пептид или пептидомиметик, который связывается с рецептором тромбоэтина, фармацевтическая композиция и способ лечения |
US5963666A (en) * | 1995-08-18 | 1999-10-05 | International Business Machines Corporation | Confusion matrix mediated word prediction |
US6040335A (en) * | 1995-10-17 | 2000-03-21 | Suntory Limited | Therapeutics for thrombocytopenia |
TR199802401T2 (xx) | 1996-05-22 | 1999-03-22 | Smithkline Beecham Corporation | Peptid olmayan G-CSF mimetikleri. |
WO1998009967A1 (fr) | 1996-09-09 | 1998-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Derives de pyrrolocarbazole |
US5932546A (en) * | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
JPH10212289A (ja) | 1997-01-31 | 1998-08-11 | Kyowa Hakko Kogyo Co Ltd | ピロロフェナンスリジン誘導体 |
WO1999011262A1 (en) | 1997-09-02 | 1999-03-11 | Roche Diagnostics Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia |
JPH11152276A (ja) | 1997-11-20 | 1999-06-08 | Hokuriku Seiyaku Co Ltd | ベンゾジアゼピン誘導体 |
JP2000044562A (ja) | 1998-07-31 | 2000-02-15 | Kyowa Hakko Kogyo Co Ltd | ピロロフタルイミド誘導体 |
JP2002526482A (ja) | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | p38のインヒビター |
DE69929464T2 (de) * | 1998-11-17 | 2006-09-07 | Smithkline Beecham Corp. | Zyklische polyamine zur behandlung der thrombozytopenie |
GC0000177A (en) | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
AU6023300A (en) | 1999-07-26 | 2001-02-13 | Shionogi & Co., Ltd. | Drug compositions exhibiting thrombopoietin agonism |
TWI284639B (en) * | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
GB0028383D0 (en) * | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
ATE553758T1 (de) | 2000-12-18 | 2012-05-15 | Inst Med Molecular Design Inc | Hemmer für die produktion und freisetzung entzündlicher zytokine |
WO2002053160A1 (en) | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Method for treating glaucoma ivb |
EP1357116A4 (en) * | 2001-02-02 | 2005-06-01 | Yamanouchi Pharma Co Ltd | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF |
US7199124B2 (en) | 2001-02-02 | 2007-04-03 | Takeda Pharmaceutical Company Limited | JNK inhibitor |
PT1466912E (pt) | 2002-01-18 | 2013-06-28 | Astellas Pharma Inc | Derivado de 2-aciloaminotiazol ou seu sal |
CN101613321A (zh) | 2002-03-05 | 2009-12-30 | 特兰斯泰克制药公司 | 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物 |
EP1513534A2 (en) | 2002-04-04 | 2005-03-16 | Cv Therapeutics, Inc. | Compounds for increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis |
WO2003103657A1 (ja) | 2002-06-11 | 2003-12-18 | 株式会社医薬分子設計研究所 | 神経変性疾患治療剤 |
MXPA05000130A (es) | 2002-06-27 | 2005-02-17 | Novo Nordisk As | Derivados de aril-carbonilo como agentes terapeuticos. |
AU2003268687A1 (en) | 2002-09-30 | 2004-04-19 | Yamanouchi Pharmaceutical Co., Ltd. | Novel salt of 2-acylaminothiazole derivative |
CA2514363A1 (en) | 2003-02-12 | 2004-08-26 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
JP2006524688A (ja) * | 2003-03-25 | 2006-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチアゾール |
KR100907317B1 (ko) * | 2003-07-17 | 2009-07-13 | 아스텔라스세이야쿠 가부시키가이샤 | 2-아실아미노티아졸 유도체 또는 그의 염 |
EP1655291B1 (en) | 2003-08-12 | 2016-08-03 | Shionogi & Co., Ltd. | Compounds having thrombopoietin receptor agonism |
US20070203153A1 (en) | 2005-11-08 | 2007-08-30 | Astellas Pharma Inc. | Compositions and methods for treating thrombocytopenia |
ES2452032T3 (es) | 2006-08-08 | 2014-03-31 | Akarx, Inc. | Composiciones y métodos para aumentar los niveles de plaquetas de la sangre en humanos |
-
2003
- 2003-01-15 PT PT37005717T patent/PT1466912E/pt unknown
- 2003-01-15 JP JP2003562111A patent/JP4120586B2/ja not_active Expired - Lifetime
- 2003-01-15 US US10/500,964 patent/US7638536B2/en active Active
- 2003-01-15 EP EP03700571.7A patent/EP1466912B1/en not_active Expired - Lifetime
- 2003-01-15 KR KR1020047010846A patent/KR101010905B1/ko active IP Right Grant
- 2003-01-15 EP EP11154632.1A patent/EP2314586B1/en not_active Expired - Lifetime
- 2003-01-15 ES ES03700571T patent/ES2416304T3/es not_active Expired - Lifetime
- 2003-01-15 ES ES11154632.1T patent/ES2610611T3/es not_active Expired - Lifetime
- 2003-01-15 SI SI200332274T patent/SI1466912T1/sl unknown
- 2003-01-15 CN CNB038044579A patent/CN1319967C/zh not_active Expired - Lifetime
- 2003-01-15 CA CA2472711A patent/CA2472711C/en not_active Expired - Lifetime
- 2003-01-15 DK DK03700571.7T patent/DK1466912T3/da active
- 2003-01-15 WO PCT/JP2003/000270 patent/WO2003062233A1/ja active Application Filing
-
2008
- 2008-02-04 JP JP2008023950A patent/JP4844574B2/ja not_active Expired - Lifetime
-
2009
- 2009-11-10 US US12/615,979 patent/US20100222329A1/en not_active Abandoned
- 2009-11-10 US US12/615,968 patent/US8338429B2/en not_active Expired - Lifetime
-
2012
- 2012-11-15 US US13/677,520 patent/US8765764B2/en not_active Expired - Lifetime
-
2013
- 2013-07-24 CY CY20131100629T patent/CY1114169T1/el unknown
-
2019
- 2019-11-06 BE BE2019C547C patent/BE2019C547I2/fr unknown
- 2019-11-12 LU LU00137C patent/LUC00137I2/fr unknown
- 2019-12-06 FR FR19C1072C patent/FR19C1072I2/fr active Active
- 2019-12-11 HU HUS1900052C patent/HUS1900052I1/hu unknown
- 2019-12-11 NL NL301020C patent/NL301020I2/nl unknown
- 2019-12-17 CY CY2019045C patent/CY2019045I1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101010905B1 (ko) | 2-아실아미노티아졸 유도체 또는 그 염 | |
TWI461423B (zh) | 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物 | |
JPWO2002062775A1 (ja) | 2−アシルアミノチアゾール誘導体又はその塩 | |
WO2002006237A1 (fr) | Medicament comprenant un derive de dicyanopyridine | |
ES2375586T3 (es) | Derivados de imidazolidinona. | |
JP4324791B2 (ja) | 2−アシルアミノチアゾール誘導体又はその塩 | |
SK14952001A3 (sk) | 5-Pyridyl-1,3-azolové zlúčeniny, spôsob výroby a použitia | |
WO2012009649A1 (en) | Mif inhibitors and their uses | |
WO2002046186A1 (fr) | Dérivés thiazole substitués porteurs de groupes 3-pyridyl, procédé d'élaboration et leur utilisation | |
PH12015501899B1 (en) | 2-acylaminothiazole derivative and salt thereof | |
JP4774995B2 (ja) | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 | |
AU2021410119A1 (en) | Tetrahydroquinoline derivative and medicinal use thereof | |
KR20170013987A (ko) | 2-아실아미노티아졸 유도체 또는 그의 염 | |
WO2022250108A1 (ja) | フェニルウレア誘導体 | |
US10183013B2 (en) | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | |
KR20130013163A (ko) | 혈관생성억제 작용을 갖는 신규한 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
US20060004051A1 (en) | Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140107 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150107 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160111 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170112 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180111 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190110 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20200109 Year of fee payment: 10 |